Peer-reviewed veterinary case report
Proteasome inhibitors may help chemo work better for canine lymphoma
By Nicholas E Prevedel et al.·Published in Veterinary and Comparative Oncology·2024·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
- Species:
- dog
Plain-English summary
A study looked at how well proteasome inhibitors work with standard chemotherapy (CHOP) for dogs with lymphoma. Researchers found that certain lymphoma cells from dogs responded better to treatment when proteasome inhibitors like bortezomib and ixazomib were added to the chemotherapy drugs doxorubicin, vincristine, and cyclophosphamide. This suggests that using these inhibitors could help improve the effectiveness of chemotherapy in dogs with lymphoma. While more research is needed, these findings could lead to better treatment options for dogs facing this illness.
People also search for: dog lymphoma treatment · CHOP chemotherapy for dogs · bortezomib for canine lymphoma · improving dog cancer treatment
Abstract
The standard treatment for canine lymphoma is the CHOP chemotherapy regimen. Proteasome inhibitors have been employed with CHOP for the treatment of human haematological malignancies but remain to be fully explored in canine lymphoma. We identified an association between poor response to CHOP chemotherapy and high mRNA expression levels of proteasomal subunits in a cohort of 15 canine lymphoma patients, and sought to determine the effect of proteasome inhibitors on the viability of a canine B-cell lymphoma cell line (CLBL-1). The aim of this study was to investigate whether proteasome inhibitors sensitize these cells to the CHOP agents doxorubicin, vincristine and cyclophosphamide (as 4-hydroxycyclophosphamide/4-HC). CLBL-1 cells were sensitive to proteasome inhibition by bortezomib and ixazomib. The IC50 of bortezomib was 15.1 nM and of ixazomib was 59.14 nM. Proteasome inhibitors plus doxorubicin had a synergistic effect on CLBL-1 viability; proteosome inhibitors plus vincristine showed different effects depending on the combination ratio, and there was an antagonistic effect with 4-HC. These results may have clinical utility, as proteasome inhibition could potentially be used with a synergizing CHOP compound to improve responsiveness to chemotherapy for canine lymphoma patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/38237918